<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36757946</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>13</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>2</Issue><PubDate><Year>2023</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>A machine learning approach identifies distinct early-symptom cluster phenotypes which correlate with hospitalization, failure to return to activities, and prolonged COVID-19 symptoms.</ArticleTitle><Pagination><StartPage>e0281272</StartPage><MedlinePgn>e0281272</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0281272</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0281272</ELocationID><Abstract><AbstractText Label="BACKGROUND">Accurate COVID-19 prognosis is a critical aspect of acute and long-term clinical management. We identified discrete clusters of early stage-symptoms which may delineate groups with distinct disease severity phenotypes, including risk of developing long-term symptoms and associated inflammatory profiles.</AbstractText><AbstractText Label="METHODS">1,273 SARS-CoV-2 positive U.S. Military Health System beneficiaries with quantitative symptom scores (FLU-PRO Plus) were included in this analysis. We employed machine-learning approaches to identify symptom clusters and compared risk of hospitalization, long-term symptoms, as well as peak CRP and IL-6 concentrations.</AbstractText><AbstractText Label="RESULTS">We identified three distinct clusters of participants based on their FLU-PRO Plus symptoms: cluster 1 ("Nasal cluster") is highly correlated with reporting runny/stuffy nose and sneezing, cluster 2 ("Sensory cluster") is highly correlated with loss of smell or taste, and cluster 3 ("Respiratory/Systemic cluster") is highly correlated with the respiratory (cough, trouble breathing, among others) and systemic (body aches, chills, among others) domain symptoms. Participants in the Respiratory/Systemic cluster were twice as likely as those in the Nasal cluster to have been hospitalized, and 1.5 times as likely to report that they had not returned-to-activities, which remained significant after controlling for confounding covariates (P &lt; 0.01). Respiratory/Systemic and Sensory clusters were more likely to have symptoms at six-months post-symptom-onset (P = 0.03). We observed higher peak CRP and IL-6 in the Respiratory/Systemic cluster (P &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">We identified early symptom profiles potentially associated with hospitalization, return-to-activities, long-term symptoms, and inflammatory profiles. These findings may assist in patient prognosis, including prediction of long COVID risk.</AbstractText><CopyrightInformation>Copyright: This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Epsi</LastName><ForeName>Nusrat J</ForeName><Initials>NJ</Initials><Identifier Source="ORCID">0000-0001-5363-075X</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powers</LastName><ForeName>John H</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Clinical Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lindholm</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0001-5428-7404</Identifier><AffiliationInfo><Affiliation>Molecular Biology Laboratory, Brooke Army Medical Center, San Antonio, Texas, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mende</LastName><ForeName>Katrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Molecular Biology Laboratory, Brooke Army Medical Center, San Antonio, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malloy</LastName><ForeName>Allison</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ganesan</LastName><ForeName>Anuradha</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Clinic, Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huprikar</LastName><ForeName>Nikhil</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinic, Walter Reed National Military Medical Center, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lalani</LastName><ForeName>Tahaniyat</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Naval Medical Center Portsmouth, Portsmouth, Virginia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Alfred</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Naval Medical Center Portsmouth, Portsmouth, Virginia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mody</LastName><ForeName>Rupal M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinic, William Beaumont Army Medical Center, El Paso, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Milissa U</ForeName><Initials>MU</Initials><AffiliationInfo><Affiliation>Pediatric Infectious Diseases, Tripler Army Medical Center, Honolulu, Hawaii, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bazan</LastName><ForeName>Samantha E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Family Nurse Practitioner and Women's Health Nurse Practitioner Program, Carl R. Darnall Army Medical Center, Fort Hood, Texas, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Rhonda E</ForeName><Initials>RE</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Clinic, Madigan Army Medical Center, Tacoma, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>Christopher J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinic, Madigan Army Medical Center, Tacoma, Washington, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ewers</LastName><ForeName>Evan C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Internal Medicine, Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Larson</LastName><ForeName>Derek T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Internal Medicine, Fort Belvoir Community Hospital, Fort Belvoir, Virginia, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Clinic, Naval Medical Center San Diego, San Diego, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berjohn</LastName><ForeName>Catherine M</ForeName><Initials>CM</Initials><Identifier Source="ORCID">0000-0001-5655-8183</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Clinic, Naval Medical Center San Diego, San Diego, California, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maldonado</LastName><ForeName>Carlos J</ForeName><Initials>CJ</Initials><Identifier Source="ORCID">0000-0002-7484-9942</Identifier><AffiliationInfo><Affiliation>Department of Research and Clinical Investigation, Womack Army Medical Center, Fort Bragg, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blair</LastName><ForeName>Paul W</ForeName><Initials>PW</Initials><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chenoweth</LastName><ForeName>Josh</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saunders</LastName><ForeName>David L</ForeName><Initials>DL</Initials><AffiliationInfo><Affiliation>Translational Medicine Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Livezey</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Medicine Unit, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maves</LastName><ForeName>Ryan C</ForeName><Initials>RC</Initials><Identifier Source="ORCID">0000-0001-6234-6160</Identifier><AffiliationInfo><Affiliation>Infectious Diseases and Critical Care Medicine, Wake Forest School of Medicine, Winston-Salem, North Carolina, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez Edwards</LastName><ForeName>Margaret</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rozman</LastName><ForeName>Julia S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0003-0114-5140</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simons</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tribble</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agan</LastName><ForeName>Brian K</ForeName><Initials>BK</Initials><Identifier Source="ORCID">0000-0002-5114-1669</Identifier><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burgess</LastName><ForeName>Timothy H</ForeName><Initials>TH</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pollett</LastName><ForeName>Simon D</ForeName><Initials>SD</Initials><AffiliationInfo><Affiliation>Infectious Disease Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, Maryland, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>EPICC COVID-19 Cohort Study Group</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Y01 AI005072</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Potential conflicts of interest. S. D. P., T. H. B, D.R.T, and M.P.S. report that the Uniformed Services University (USU) Infectious Diseases Clinical Research Program (IDCRP), a US Department of Defense institution, and the Henry M. Jackson Foundation (HJF) were funded under a Cooperative Research and Development Agreement to conduct an unrelated phase III COVID-19 monoclonal antibody immunoprophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was funded by the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense to augment the conduct of an unrelated phase III vaccine trial sponsored by AstraZeneca. Both of these trials were part of the US Government COVID-19 response. Neither is related to the work presented here. This does not alter our adherence to PLOS ONE policies on sharing data and materials.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>11</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>9</Day><Hour>13</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36757946</ArticleId><ArticleId IdType="pmc">PMC9910657</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0281272</ArticleId><ArticleId IdType="pii">PONE-D-22-31484</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stokes EK, Zambrano LD, Anderson KN, et al.. Coronavirus Disease 2019 Case Surveillance&#x2014;United States, January 22-May 30, 2020. MMWR Morbidity and mortality weekly report 2020; 69(24): 759&#x2013;65. doi: 10.15585/mmwr.mm6924e2</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm6924e2</ArticleId><ArticleId IdType="pmc">PMC7302472</ArticleId><ArticleId IdType="pubmed">32555134</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorci G, Faivre B, Morand S. Explaining among-country variation in COVID-19 case fatality rate. Scientific Reports 2020; 10(1): 18909. doi: 10.1038/s41598-020-75848-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-75848-2</ArticleId><ArticleId IdType="pmc">PMC7609641</ArticleId><ArticleId IdType="pubmed">33144595</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira NL, Ahmad F, Byku M, et al.. COVID-19: Understanding Inter-Individual Variability and Implications for Precision Medicine. Mayo Clinic proceedings 2021; 96(2): 446&#x2013;63. doi: 10.1016/j.mayocp.2020.11.024</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mayocp.2020.11.024</ArticleId><ArticleId IdType="pmc">PMC7713605</ArticleId><ArticleId IdType="pubmed">33549263</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull-Otterson L BS, Saydah S, et al.. Post&#x2013;COVID Conditions Among Adult COVID-19 Survivors Aged 18&#x2013;64 and &#x2265;65 Years&#x2014;United States, March 2020&#x2013;November 2021: CDC, 2022. May 27, 2022.</Citation></Reference><Reference><Citation>Spudich S, Nath A. Nervous system consequences of COVID-19. Science (New York, NY) 2022; 375(6578): 267&#x2013;9. doi: 10.1126/science.abm2052</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm2052</ArticleId><ArticleId IdType="pubmed">35050660</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold DT, Hamilton FW, Milne A, et al.. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax 2021; 76(4): 399&#x2013;401. doi: 10.1136/thoraxjnl-2020-216086</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/thoraxjnl-2020-216086</ArticleId><ArticleId IdType="pmc">PMC7716340</ArticleId><ArticleId IdType="pubmed">33273026</ArticleId></ArticleIdList></Reference><Reference><Citation>Cirulli ET, Schiabor Barrett KM, Riffle S, et al.. Long-term COVID-19 symptoms in a large unselected population. medRxiv: the preprint server for health sciences 2020: 2020.10.07.20208702.</Citation></Reference><Reference><Citation>Bellan M, Soddu D, Balbo PE, et al.. Respiratory and Psychophysical Sequelae Among Patients With COVID-19 Four Months After Hospital Discharge. JAMA network open 2021; 4(1): e2036142. doi: 10.1001/jamanetworkopen.2020.36142</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.36142</ArticleId><ArticleId IdType="pmc">PMC7841464</ArticleId><ArticleId IdType="pubmed">33502487</ArticleId></ArticleIdList></Reference><Reference><Citation>Dennis A, Wamil M, Alberts J, et al.. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: a prospective, community-based study. BMJ open 2021; 11(3): e048391. doi: 10.1136/bmjopen-2020-048391</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-048391</ArticleId><ArticleId IdType="pmc">PMC8727683</ArticleId><ArticleId IdType="pubmed">33785495</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, et al.. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalMedicine 2021; 38: 101019. doi: 10.1016/j.eclinm.2021.101019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J Infect Dis 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, Epsi NJ, Pollett S, et al.. Performance of the inFLUenza Patient-Reported Outcome Plus (FLU-PRO Plus) Instrument in Patients With Coronavirus Disease 2019. Open Forum Infectious Diseases 2021; 8(12). doi: 10.1093/ofid/ofab517</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab517</ArticleId><ArticleId IdType="pmc">PMC8661080</ArticleId><ArticleId IdType="pubmed">34901299</ArticleId></ArticleIdList></Reference><Reference><Citation>Araiza A, Duran M, Pati&#xf1;o C, Marik PE, Varon J. The Ichikado CT score as a prognostic tool for coronavirus disease 2019 pneumonia: a retrospective cohort study. Journal of intensive care 2021; 9(1): 51. doi: 10.1186/s40560-021-00566-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-021-00566-4</ArticleId><ArticleId IdType="pmc">PMC8379600</ArticleId><ArticleId IdType="pubmed">34419163</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng L, Dong D, Li L, et al.. A Deep Learning Prognosis Model Help Alert for COVID-19 Patients at High-Risk of Death: A Multi-Center Study. IEEE journal of biomedical and health informatics 2020; 24(12): 3576&#x2013;84. doi: 10.1109/JBHI.2020.3034296</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/JBHI.2020.3034296</ArticleId><ArticleId IdType="pmc">PMC8545180</ArticleId><ArticleId IdType="pubmed">33108303</ArticleId></ArticleIdList></Reference><Reference><Citation>Haimovich AD, Ravindra NG, Stoytchev S, et al.. Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Annals of emergency medicine 2020; 76(4): 442&#x2013;53. doi: 10.1016/j.annemergmed.2020.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2020.07.022</ArticleId><ArticleId IdType="pmc">PMC7373004</ArticleId><ArticleId IdType="pubmed">33012378</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenny G, McCann K, O&#x2019;Brien C, et al.. Identification of Distinct Long COVID Clinical Phenotypes Through Cluster Analysis of Self-Reported Symptoms. Open Forum Infect Dis 2022; 9(4): ofac060. doi: 10.1093/ofid/ofac060</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofac060</ArticleId><ArticleId IdType="pmc">PMC8900926</ArticleId><ArticleId IdType="pubmed">35265728</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Lee KA, Lochlainn MN, et al.. Symptom clusters in COVID-19: A potential clinical prediction tool from the COVID Symptom Study app. Science advances 2021; 7(12). doi: 10.1126/sciadv.abd4177</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abd4177</ArticleId><ArticleId IdType="pmc">PMC7978420</ArticleId><ArticleId IdType="pubmed">33741586</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng X, Wan H, Yuan H, et al.. Symptom Clustering Patterns and Population Characteristics of COVID-19 Based on Text Clustering Method. Frontiers in public health 2022; 10: 795734. doi: 10.3389/fpubh.2022.795734</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2022.795734</ArticleId><ArticleId IdType="pmc">PMC8854172</ArticleId><ArticleId IdType="pubmed">35186839</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong-Chew RM, Rodr&#xed;guez Cabrera EX, Rodr&#xed;guez Valdez CA, et al.. Symptom cluster analysis of long COVID-19 in patients discharged from the Temporary COVID-19 Hospital in Mexico City. Therapeutic advances in infectious disease 2022; 9: 20499361211069264. doi: 10.1177/20499361211069264</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20499361211069264</ArticleId><ArticleId IdType="pmc">PMC8764618</ArticleId><ArticleId IdType="pubmed">35059196</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;emes A, Ray S, Aboumerhi K, et al.. A syndromic surveillance tool to detect anomalous clusters of COVID-19 symptoms in the United States. Sci Rep 2021; 11(1): 4660. doi: 10.1038/s41598-021-84145-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-84145-5</ArticleId><ArticleId IdType="pmc">PMC7907397</ArticleId><ArticleId IdType="pubmed">33633250</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, Epsi NJ, Lindholm DA, et al.. COVID-19 patient reported symptoms using FLU-PRO Plus in a cohort study: associations with infecting genotype, vaccine history, and return-to-health. Open Forum Infectious Diseases 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214183</ArticleId><ArticleId IdType="pubmed">35873301</ArticleId></ArticleIdList></Reference><Reference><Citation>Richard SA, Pollett SD, Lanteri CA, et al.. COVID-19 Outcomes Among US Military Health System Beneficiaries Include Complications Across Multiple Organ Systems and Substantial Functional Impairment. Open Forum Infectious Diseases 2021; 8(12). doi: 10.1093/ofid/ofab556</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab556</ArticleId><ArticleId IdType="pmc">PMC8664684</ArticleId><ArticleId IdType="pubmed">34909439</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of chronic diseases 1987; 40(5): 373&#x2013;83. doi: 10.1016/0021-9681(87)90171-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0021-9681(87)90171-8</ArticleId><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JH, Guerrero ML, Leidy NK, et al.. Development of the Flu-PRO: a patient-reported outcome (PRO) instrument to evaluate symptoms of influenza. BMC Infectious Diseases 2016; 16(1): 1. doi: 10.1186/s12879-015-1330-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-015-1330-0</ArticleId><ArticleId IdType="pmc">PMC4700740</ArticleId><ArticleId IdType="pubmed">26729246</ArticleId></ArticleIdList></Reference><Reference><Citation>Han A, Poon J-L, Powers JH, Leidy NK, Yu R, Memoli MJ. Using the Influenza Patient-reported Outcome (FLU-PRO) diary to evaluate symptoms of influenza viral infection in a healthy human challenge model. BMC Infectious Diseases 2018; 18(1): 353. doi: 10.1186/s12879-018-3220-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-018-3220-8</ArticleId><ArticleId IdType="pmc">PMC6064178</ArticleId><ArticleId IdType="pubmed">30055573</ArticleId></ArticleIdList></Reference><Reference><Citation>Powers JH 3rd, Bacci ED, Leidy NK, et al.. Performance of the inFLUenza Patient-Reported Outcome (FLU-PRO) diary in patients with influenza-like illness (ILI). PloS one 2018; 13(3): e0194180. doi: 10.1371/journal.pone.0194180</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0194180</ArticleId><ArticleId IdType="pmc">PMC5863969</ArticleId><ArticleId IdType="pubmed">29566007</ArticleId></ArticleIdList></Reference><Reference><Citation>Freed NE, Vlkov&#xe1; M, Faisal MB, Silander OK. Rapid and inexpensive whole-genome sequencing of SARS-CoV-2 using 1200 bp tiled amplicons and Oxford Nanopore Rapid Barcoding. Biology methods &amp; protocols 2020; 5(1): bpaa014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454405</ArticleId><ArticleId IdType="pubmed">33029559</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaut A, Holmes EC, O&#x2019;Toole &#xc1;, et al.. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nature microbiology 2020; 5(11): 1403&#x2013;7. doi: 10.1038/s41564-020-0770-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41564-020-0770-5</ArticleId><ArticleId IdType="pmc">PMC7610519</ArticleId><ArticleId IdType="pubmed">32669681</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair PW, Brandsma J, Chenoweth J, et al.. Topological data analysis identifies distinct biomarker phenotypes during the &#x2018;inflammatory&#x2019; phase of COVID-19. 2021: 2021.12.25.21268206.</Citation></Reference><Reference><Citation>Epsi NJ, Richard SA, Lindholm DA, et al.. Understanding &#x2019;hybrid immunity&#x2019;: comparison and predictors of humoral immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 2022. doi: 10.1093/cid/ciac392</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac392</ArticleId><ArticleId IdType="pmc">PMC9213853</ArticleId><ArticleId IdType="pubmed">35608504</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearson K. On lines and planes of closest fit to systems of points in space. The London, Edinburgh, Dublin philosophical magazine journal of science 1901; 2(11): 559&#x2013;72.</Citation></Reference><Reference><Citation>Ding C, He X. K-means clustering via principal component analysis. In: Proceedings of the twenty-first international conference on Machine learning, 2004:29.</Citation></Reference><Reference><Citation>Tibshirani R, Walther G, Hastie T. Estimating the number of clusters in a data set via the gap statistic. Journal of the Royal Statistical Society 2001; 63(2): 411&#x2013;23.</Citation></Reference><Reference><Citation>Team TRDC. R: A language environment for statistical computing. R Foundation for Statistical Computing. 2020.</Citation></Reference><Reference><Citation>Epsi NJ, Richard SA, Laing ED, et al.. Clinical, immunological and virological SARS-CoV-2 phenotypes in obese and non-obese military health system beneficiaries. The Journal of Infectious Diseases 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8385847</ArticleId><ArticleId IdType="pubmed">34331541</ArticleId></ArticleIdList></Reference><Reference><Citation>Mueller AL, McNamara MS, Sinclair DA. Why does COVID-19 disproportionately affect older people? Aging 2020; 12(10): 9959&#x2013;81. doi: 10.18632/aging.103344</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/aging.103344</ArticleId><ArticleId IdType="pmc">PMC7288963</ArticleId><ArticleId IdType="pubmed">32470948</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges do Nascimento IJ, Cacic N, Abdulazeem HM, et al.. Novel Coronavirus Infection (COVID-19) in Humans: A Scoping Review and Meta-Analysis. Journal of clinical medicine 2020; 9(4). doi: 10.3390/jcm9040941</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9040941</ArticleId><ArticleId IdType="pmc">PMC7230636</ArticleId><ArticleId IdType="pubmed">32235486</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J, Zheng Y, Gou X, et al.. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International journal of infectious diseases: IJID: official publication of the International Society for Infectious Diseases 2020; 94: 91&#x2013;5. doi: 10.1016/j.ijid.2020.03.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.03.017</ArticleId><ArticleId IdType="pmc">PMC7194638</ArticleId><ArticleId IdType="pubmed">32173574</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D, Hu B, Hu C, et al.. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama 2020; 323(11): 1061&#x2013;9. doi: 10.1001/jama.2020.1585</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dani M, Dirksen A, Taraborrelli P, et al.. Autonomic dysfunction in &#x2019;long COVID&#x2019;: rationale, physiology and management strategies. Clinical medicine (London, England) 2021; 21(1): e63&#x2013;e7. doi: 10.7861/clinmed.2020-0896</Citation><ArticleIdList><ArticleId IdType="doi">10.7861/clinmed.2020-0896</ArticleId><ArticleId IdType="pmc">PMC7850225</ArticleId><ArticleId IdType="pubmed">33243837</ArticleId></ArticleIdList></Reference><Reference><Citation>Eshak N, Abdelnabi M, Ball S, et al.. Dysautonomia: An Overlooked Neurological Manifestation in a Critically ill COVID-19 Patient. The American journal of the medical sciences 2020; 360(4): 427&#x2013;9. doi: 10.1016/j.amjms.2020.07.022</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjms.2020.07.022</ArticleId><ArticleId IdType="pmc">PMC7366085</ArticleId><ArticleId IdType="pubmed">32739039</ArticleId></ArticleIdList></Reference><Reference><Citation>de Melo GD, Lazarini F, Levallois S, et al.. COVID-19-related anosmia is associated with viral persistence and inflammation in human olfactory epithelium and brain infection in hamsters. Science translational medicine 2021; 13(596). doi: 10.1126/scitranslmed.abf8396</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abf8396</ArticleId><ArticleId IdType="pmc">PMC8158965</ArticleId><ArticleId IdType="pubmed">33941622</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F, Kream RM, Stefano GB. Long-Term Respiratory and Neurological Sequelae of COVID-19. Medical science monitor: international medical journal of experimental and clinical research 2020; 26: e928996. doi: 10.12659/MSM.928996</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.928996</ArticleId><ArticleId IdType="pmc">PMC7643287</ArticleId><ArticleId IdType="pubmed">33177481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rass V, Tymoszuk P, Sahanic S, et al.. Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae. 2022: 2022.06.02.22275932.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10562286</ArticleId><ArticleId IdType="pubmed">37670171</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F, Li L, Xu M, et al.. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology 2020; 127: 104370. doi: 10.1016/j.jcv.2020.104370</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcv.2020.104370</ArticleId><ArticleId IdType="pmc">PMC7194648</ArticleId><ArticleId IdType="pubmed">32344321</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold T, Jurinovic V, Arnreich C, et al.. Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. The Journal of allergy and clinical immunology 2020; 146(1): 128-36.e4. doi: 10.1016/j.jaci.2020.05.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.05.008</ArticleId><ArticleId IdType="pmc">PMC7233239</ArticleId><ArticleId IdType="pubmed">32425269</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhattacharyya RP, Hanage WP. Challenges in Inferring Intrinsic Severity of the SARS-CoV-2 Omicron Variant. 2022; 386(7): e14.</Citation><ArticleIdList><ArticleId IdType="pubmed">35108465</ArticleId></ArticleIdList></Reference><Reference><Citation>Kozlov M. Omicron&#x2019;s feeble attack on the lungs could make it less dangerous. Nature 2022; 601(7892): 177. doi: 10.1038/d41586-022-00007-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-022-00007-8</ArticleId><ArticleId IdType="pubmed">34987210</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies MA, Kassanjee R, Rousseau P, et al.. Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa. Tropical medicine &amp; international health: TM &amp; IH 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9115442</ArticleId><ArticleId IdType="pubmed">35411997</ArticleId></ArticleIdList></Reference><Reference><Citation>Willett BJ, Grove J, MacLean OA, et al.. The hyper-transmissible SARS-CoV-2 Omicron variant exhibits significant antigenic change, vaccine escape and a switch in cell entry mechanism. 2022: 2022.01.03.21268111.</Citation></Reference><Reference><Citation>Meng B, Abdullahi A, Ferreira IATM, et al.. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature 2022; 603(7902): 706&#x2013;14. doi: 10.1038/s41586-022-04474-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>